We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Galectin-3 Test to Provide Information About Heart Failure

By LabMedica International staff writers
Posted on 29 Apr 2010
A galectin-3 test will be developed to provide additional information about a patient's heart failure.

Patients with elevated galectin-3 levels have a worse prognosis in terms of mortality or risk of hospitalization than comparable patients with low or normal levels of galectin-3 have. Measurement of galectin-3 in patients with heart failure offers clinically useful information that physicians can use as an aid in the stratification of patients diagnosed with heart failure.

BG Medicine, Inc. (Waltham, MA, USA) announced that it has entered into an agreement with Inverness Medical Innovations, Inc. (Waltham, MA, USA) for the development and commercialization of the galectin-3 test for Inverness' Triage Meter Pro.

Inverness will be responsible for the development of the test in accordance with agreed plans and milestones, and Inverness and BG Medicine will collaborate in support of development of the test and regulatory filings.

"BNP [B-natriuretic peptide] and galectin-3 each provide important independent information about a patient's heart failure,” said Pieter Muntendam, M.D., president and CEO of BG Medicine. "This business opportunity was created by the natural complementarity of the two tests.”

Upregulated in hypertrophied hearts, galectin-3 stimulates macrophage migration, fibroblast proliferation, and the development of fibrosis. Cardiac fibrosis and remodeling adversely impact outcomes in HF, being linked to disease progression. Measurement of galectin-3 in patients with HF may help identify patients at highest risk for readmission or death, potentially enabling care tailored to individual patient needs.

Inverness Medical Innovations is a leader in rapid point-of-care diagnostics; its products focus on infectious disease, cardiology, oncology, drugs of abuse, and women's health.

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs.

Related Links:
BG Medicine, Inc.
Inverness Medical Innovations, Inc.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Manual Pipetting Aid
Pipette Controllers macro
HPV Test
Allplex HPV28 Detection

Latest Immunology News

Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
29 Apr 2010  |   Immunology

Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
29 Apr 2010  |   Immunology

Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
29 Apr 2010  |   Immunology